Skip to main content
Journal cover image

Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.

Publication ,  Journal Article
Caram, MEV; Guo, C; Leja, M; Smerage, J; Henry, NL; Giacherio, D; Rubenfire, M; Schott, A; Davis, M; Hayes, DF; Van Poznak, C; Cooney, KA ...
Published in: Breast Cancer Res Treat
July 2015

Cardiomyopathy is a known complication of anthracycline-based adjuvant chemotherapy and is more commonly reported in population-based studies of breast cancer survivors than in clinical trials. This study prospectively evaluated the prevalence of elevated cardiac biomarkers in unselected patients who had been treated with doxorubicin for early-stage breast cancer and the prevalence of reduced LVEF in patients with an elevated biomarker. All participants underwent an examination, symptom inventory, medical record review, and biomarker analysis for BNP, troponin, and plasma and urine NT-proBNP. Patients who had one or more elevated biomarkers were referred for echocardiogram; systolic dysfunction was defined as LVEF less than 55 %. Multivariable logistic regression was used to determine the associations between age, BMI, cumulative dose of doxorubicin, diabetes, hypertension, and left-sided radiation therapy and the risk of reduced LVEF. Among the 269 patients who underwent lab testing (mean age 56 years, mean time since completion of doxorubicin-based chemotherapy 6 years), 192 (72 %) had one or more elevated biomarker. Among the 166 patients who completed an echocardiogram, 11.5 % had a LVEF < 55 %. After adjusting for covariates known to affect cardiac function, multivariable logistic regression revealed plasma NT-proBNP to be the only measured cardiac biomarker associated with systolic dysfunction. There is a relationship between NT-proBNP and the frequency of reduced LVEF in women treated with doxorubicin for curative intent; further study of NT-proBNP as a potential biomarker for subclinical cardiac dysfunction after exposure to anthracyclines is warranted.

Duke Scholars

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

July 2015

Volume

152

Issue

1

Start / End Page

163 / 172

Location

Netherlands

Related Subject Headings

  • Risk Factors
  • Prevalence
  • Population Surveillance
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Heart Diseases
  • Female
  • Echocardiography
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Caram, M. E. V., Guo, C., Leja, M., Smerage, J., Henry, N. L., Giacherio, D., … Griggs, J. J. (2015). Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat, 152(1), 163–172. https://doi.org/10.1007/s10549-015-3454-8
Caram, Megan E. V., Cui Guo, Monika Leja, Jeffrey Smerage, N Lynn Henry, Donald Giacherio, Melvyn Rubenfire, et al. “Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.Breast Cancer Res Treat 152, no. 1 (July 2015): 163–72. https://doi.org/10.1007/s10549-015-3454-8.
Caram MEV, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, et al. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat. 2015 Jul;152(1):163–72.
Caram, Megan E. V., et al. “Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.Breast Cancer Res Treat, vol. 152, no. 1, July 2015, pp. 163–72. Pubmed, doi:10.1007/s10549-015-3454-8.
Caram MEV, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, Hertz DL, Banerjee M, Griggs JJ. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat. 2015 Jul;152(1):163–172.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

July 2015

Volume

152

Issue

1

Start / End Page

163 / 172

Location

Netherlands

Related Subject Headings

  • Risk Factors
  • Prevalence
  • Population Surveillance
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Heart Diseases
  • Female
  • Echocardiography